Does response to antiviral therapy affect the clinical long-term outcome of hepatitis delta?
A Wranke, B Calle Serrano, B Heidrich, J Kirschner, B Bremer, S Hardtke, K Deterding, K Port, M Cornberg, MP Manns, H Wedemeyer · Zeitschrift für Gastroenterologie · 2016 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background: Hepatitis delta is the most severe form of viral hepatitis. Pegylated interferon alpha (PEG-IFNa) is effective in only 25 – 30% of patients and associated with frequent side effects. The aim of this study was to analyze the outcome of hepatitis delta according to different management strategies (no treatment, nucleos(t)ide therapies, interferon-based therapies). Methods: Out of more than 350 anti-HDV-positive patients with chronic hepatitis delta, we selected 136 individuals who were followed for at least 6 months. The median time of follow up was 5.2 years (range 0.6 – 18.8 years). The mean age was…
